Patents

Coegin Pharma has a solid patent portfolio with 21 patent families including substance patents, user patents, combination patents and formulation patents. The patent families in the table below have been filed in the United States, Europe, Canada, Japan, Australia and also in other areas such as China, Hong Kong, Korea, India, Israel, New Zealand and Norway

Selected patent families

Novel compositions and uses thereof

PCT/GB2012/051955

Peptides for treatment of diabetes

PCT/EP2018/061547

Peptides fragments for treatment of diabetes

PCT/EP2019/080563

Topical formulation of FOL005

PCT/EP2020/061453

Peptides for use in skin and hair pigmentation

PCT/EP2021/080032

AVX001/AVX002 type compounds – treatment of psoriasis

 

PCT/GB03/000364

AVX001 type ketones for the treatment of glomerulonephritis

PCT/EP2010/003384

Oxothiazole compounds and their use for the treatment of certain

chronic inflammatory conditions

PCT/2010/064687

Oxothiazole compounds and their use in the treatment of chronic

inflammatory disorders and proliferative disorders such as cancer

PCT/EP2014/051655

Oxothiazole compounds and their use for the treatment of chronic inflammatory disorders and proliferative disorders such as cancer

PCT/EP2015/067836

AVX001 type ketones for the treatment of skin cancer

PCT/EP2015/061534

AVX001 and AVX002 in combination with BEZ235

PCT/EP2017/056022

AVX235 and AVX420 in combination with BEZ235

PCT/EP2017/056016

Formulation comprising AVX001 type ketones and silicone

PCT/EP2017/073951

Oxothiazole compounds in combination with a secosteroid

PCT/EP2017/078169

Oxothiazole compounds in combination with a corticosteroid

PCT/EP2017/078162

AVX001 type ketones for the treatment of fibrotic diseases

PCT/EP2018/066028

Oxothiazole compounds for the treatment of fibrotic diseases

PCT/EP2019/060544

AVX001/AVX002 type compounds for use in the prevention of metastasis in cancer

PCT/EP2020/071168

Novel compositions and uses thereof

PCT/GB2012/051955

Peptides for treatment of diabetes

PCT/EP2018/061547